These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Virologic Efficacy of Casirivimab and Imdevimab COVID-19 Antibody Combination in Outpatients With SARS-CoV-2 Infection: A Phase 2 Dose-Ranging Randomized Clinical Trial. Portal-Celhay C; Forleo-Neto E; Eagan W; Musser BJ; Davis JD; Turner KC; Norton T; Hooper AT; Hamilton JD; Pan C; Mahmood A; Baum A; Kyratsous CA; Kim Y; Parrino J; Kampman W; Roque-Guerrero L; Stoici R; Fatakia A; Soo Y; Geba GP; Kowal B; DiCioccio AT; Stahl N; Lipsich L; Braunstein N; Herman GA; Yancopoulos GD; Weinreich DM; JAMA Netw Open; 2022 Aug; 5(8):e2225411. PubMed ID: 35969402 [TBL] [Abstract][Full Text] [Related]
7. Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial. O'Brien MP; Forleo-Neto E; Sarkar N; Isa F; Hou P; Chan KC; Musser BJ; Bar KJ; Barnabas RV; Barouch DH; Cohen MS; Hurt CB; Burwen DR; Marovich MA; Brown ER; Heirman I; Davis JD; Turner KC; Ramesh D; Mahmood A; Hooper AT; Hamilton JD; Kim Y; Purcell LA; Baum A; Kyratsous CA; Krainson J; Perez-Perez R; Mohseni R; Kowal B; DiCioccio AT; Geba GP; Stahl N; Lipsich L; Braunstein N; Herman G; Yancopoulos GD; Weinreich DM; JAMA; 2022 Feb; 327(5):432-441. PubMed ID: 35029629 [TBL] [Abstract][Full Text] [Related]
8. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. Kreuzberger N; Hirsch C; Chai KL; Tomlinson E; Khosravi Z; Popp M; Neidhardt M; Piechotta V; Salomon S; Valk SJ; Monsef I; Schmaderer C; Wood EM; So-Osman C; Roberts DJ; McQuilten Z; Estcourt LJ; Skoetz N Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013825. PubMed ID: 34473343 [TBL] [Abstract][Full Text] [Related]
9. Clinical efficacy of casirivimab-imdevimab antibody combination treatment in patients with COVID-19 Delta variant. Miyashita N; Nakamori Y; Ogata M; Fukuda N; Yamura A; Ishiura Y J Infect Chemother; 2022 Sep; 28(9):1344-1346. PubMed ID: 35637130 [TBL] [Abstract][Full Text] [Related]
10. Association of Subcutaneous or Intravenous Administration of Casirivimab and Imdevimab Monoclonal Antibodies With Clinical Outcomes in Adults With COVID-19. McCreary EK; Bariola JR; Wadas RJ; Shovel JA; Wisniewski MK; Adam M; Albin D; Minnier T; Schmidhofer M; Meyers R; Marroquin OC; Collins K; Garrard W; Berry LR; Berry S; Crawford AM; McGlothlin A; Linstrum K; Nakayama A; Montgomery SK; Snyder GM; Yealy DM; Angus DC; Kip PL; Seymour CW; Huang DT; Kip KE JAMA Netw Open; 2022 Apr; 5(4):e226920. PubMed ID: 35412625 [TBL] [Abstract][Full Text] [Related]
11. Curbing the Delta Surge: Clinical Outcomes After Treatment With Bamlanivimab-Etesevimab, Casirivimab-Imdevimab, or Sotrovimab for Mild to Moderate Coronavirus Disease 2019. Razonable RR; O'Horo JC; Challener DW; Arndt L; Arndt RF; Clune CG; Culbertson TL; Hall ST; Heyliger A; Jackson TA; Kennedy BD; Larsen J; Hanson SN; Sweeten PW; Tulledge-Scheitel SM; Ganesh R Mayo Clin Proc; 2022 Sep; 97(9):1641-1648. PubMed ID: 36058578 [TBL] [Abstract][Full Text] [Related]
12. Clinical Prognosis of Patients With Mild COVID-19 Treated With Casirivimab/Imdevimab in Japan. Osugi Y; Iwata H; Imai Y; Kobayashi D; Hirashima R Cureus; 2022 Feb; 14(2):e21882. PubMed ID: 35273850 [TBL] [Abstract][Full Text] [Related]
13. Impact of a subcutaneous casirivimab and imdevimab clinic in outpatients with symptomatic COVID-19: A single-center, propensity-matched cohort study. Rhudy C; Bochenek S; Thomas J; St James G; Zeltner M; Platt T Am J Health Syst Pharm; 2023 Jan; 80(3):130-136. PubMed ID: 36264659 [TBL] [Abstract][Full Text] [Related]
14. Real-world clinical outcomes of treatment with casirivimab-imdevimab among patients with mild-to-moderate coronavirus disease 2019 during the Delta variant pandemic. Suzuki Y; Shibata Y; Minemura H; Nikaido T; Tanino Y; Fukuhara A; Kanno R; Saito H; Suzuki S; Ishii T; Inokoshi Y; Sando E; Sakuma H; Kobayashi T; Kume H; Kamimoto M; Aoki H; Takama A; Kamiyama T; Nakayama M; Saito K; Tanigawa K; Sato M; Kanbe T; Kanzaki N; Azuma T; Sakamoto K; Nakamura Y; Ohtani H; Waragai M; Maeda S; Ishida T; Sugino K; Tsukada Y; Yamada R; Sato R; Onuma T; Tomita H; Saito M; Watanabe N; Rikimaru M; Kawamata T; Umeda T; Morimoto J; Togawa R; Sato Y; Saito J; Kanazawa K; Iseki K Int J Med Sci; 2022; 19(5):834-841. PubMed ID: 35693744 [No Abstract] [Full Text] [Related]
15. Cost-effectiveness of casirivimab/imdevimab in patients with COVID-19 in the ambulatory setting. Jovanoski N; Kuznik A; Becker U; Hussein M; Briggs A J Manag Care Spec Pharm; 2022 May; 28(5):555-565. PubMed ID: 35238626 [No Abstract] [Full Text] [Related]
16. The impact of casirivimab-imdevimab antibody cocktail in patients amidst and post COVID 19 treatment: A retro-prospective comparative study in India. Joy AP; Augustine AT; Karattuthodi MS; Parambil JC; Chandrasekher D; Danisha P; Panakkal LM; Joshi MA; Azharul Haque KT; Mohammed Izudheen IK; Badaruddeen S; John RS; Murali S; Thomas AR; Sahla F; Ahmed Unni SAK; Ahmed RO; Cholamugath S Clin Epidemiol Glob Health; 2022; 14():100967. PubMed ID: 35071825 [TBL] [Abstract][Full Text] [Related]
17. Casirivimab/Imdevimab: First Approval. Deeks ED Drugs; 2021 Nov; 81(17):2047-2055. PubMed ID: 34716907 [TBL] [Abstract][Full Text] [Related]